BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
2.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B23.2.2026 13:10:00 CET | Press release
Industry Leading UAS Expands Mission Roles To Include Naval Strike SAN DIEGO, CA / ACCESS Newswire / February 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is developing the addition of long-range standoff weapons to its top-of-the-line MQ-9B SkyGuardian® and SeaGuardian®. Demand continues from naval and air warfighters for platforms that can hold targets at risk from great ranges, especially over the expanses of air and water in the Western Pacific. That's why GA-ASI engineers have begun the work of adapting MQ-9B's payload, stability, range and other features to accommodate the new generation of extended-range precision weapons. "MQ-9B continues to impress in the field and we keep adding to our global customer list," said GA-ASI President David R. Alexander. "We want to continue to build value in the aircraft by expanding into more missions. MQ-9B features extraordinary payload capacity, so it only makes sense to add to our mission sets with the ability to carry long
GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise23.2.2026 13:05:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / In collaboration with the U.S. Air Force, General Atomics Aeronautical Systems, Inc. (GA-ASI) conducted its latest demonstration performing an autonomous mission out of Edwards Air Force Base in Southern California using its MQ-20 Avenger® unmanned jet and an F-22 Raptor equipped with the latest government reference autonomy software. The test, which showcased Manned-Unmanned Teaming between the F-22 and MQ-20, leveraged autonomy and the tactical data link to enable coordination between the platforms. The mission included a live engagement between the MQ-20 and the F-22 as the command aircraft flown by an onboard human pilot, highlighting the ability to receive and execute teaming commands. "We appreciate the flawless execution of this mission using the government's advanced autonomous systems," said GA-ASI President David R. Alexander. "This demo featured the integration of mission elements and the ability of autonomy to ut
GA-ASI Announces YFQ-42A Dark Merlin23.2.2026 13:00:00 CET | Press release
Uncrewed Fighter Jet Takes Inspiration From Nimble Predator SAN DIEGO, CA / ACCESS Newswire / February 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is giving its U.S. Air Force Collaborative Combat Aircraft a new name: YFQ-42A Dark Merlin. Dark merlins, deadly falcons known for their black feathers and devouring of other falcons as prey, often collaborate in groups for maximum effect against their targets. The Cornell Lab of Ornithology describes the merlin as a "small, fierce falcon that uses surprise attacks" to bring down its prey in flight. The dark merlin is native to the Pacific Northwest of the United States, often migrating into southern California, where bird spotters routinely report seeing them near the YFQ-42A's manufacturing home in San Diego. The 1962 book "Profiles of the Future" imagined global technological marvels yet to change the world, offering that "any sufficiently advanced technology is indistinguishable from magic." It's no coincidence that th
Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange20.2.2026 14:08:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / February 20, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies announced today the anticipated launch of the Josh Gibson Stablecoin and dedicated Josh Gibson Name, Image, and Likeness (NIL) strategies for its forthcoming sports and entertainment focused NIL digital asset exchange. This initiative builds directly on Major League Baseball's (MLB's) historic integration of Negro Leagues (1920-1948) statistics into the official major league record and celebrates Black History Month by honoring the legacy of baseball icon Josh Gibson. As outlined in the MLB's May 2024 press release, the statistics of the Negro Leagues have officially entered the major league record, recognizing the achievements of thousands of black players previously excluded from MLB. Josh Gibson, widely regarded as one of the greatest catchers a
Masterminds Education Named "Most Nurturing Early Education Environment" at UAE Business Awards 2026; Standardizes Early Learning Model with 12-Student Class Cap Structured as Two Learning Groups of Six20.2.2026 08:35:00 CET | Press release
Dubai-based provider marks 10 consecutive years of recognition and reinforces a whole-child program delivered through ultra-small learning groups DUBAI, AE / ACCESS Newswire / February 20, 2026 / Masterminds Education announced today that it has been recognized at the UAE Business Awards 2026 with two honors: Most Nurturing Early Education Environment 2026 and Child Development Excellence Award 2026. The awards extend Masterminds' record of 10 consecutive years of recognition and reinforce the organization's focus on high-impact early education built on consistency, relationships, and outcomes. As part of strengthening the operating conditions behind the "Most Nurturing" recognition, Masterminds Early Learning Center in Dubai announced an optimization to its early education structure: beginning in the 2026-27 academic year, the Early Learning Center will operate with a maximum class size of 12 students across Preschool through KG2, organized as two learning groups of six within each cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom